PCI Biotech granted Orphan Drug Designation of fimaporfin for treatment of cholangiocarcinoma in EU NewsKristin EivindvikAugust 29, 2016
Invitation to second quarter and first half year 2016 presentation NewsKristin EivindvikAugust 24, 2016
Publication of the fimaporfin (Amphinex) first-in-man Phase I study in Lancet Oncology NewsKristin EivindvikJuly 28, 2016
PCI Biotech receives positive opinion for Orphan Drug Designation of fimaporfin for treatment of cholangiocarcinoma in EU NewsKristin EivindvikJuly 26, 2016
Pre-clinical research collaboration agreement with top-10 large pharma company extended NewsKristin EivindvikMay 26, 2016
PCI Biotech: Fourth quarter and preliminary full year 2015 results NewsKristin EivindvikFebruary 9, 2016
PCI Biotech and Ultimovacs initiates preclinical research collaboration NewsKristin EivindvikJanuary 27, 2016
Dose escalation in the bile duct cancer study completed with promising early signs of efficacy NewsKristin EivindvikJanuary 22, 2016
